Early-stage research and new pharmacological targets in Alzhei-mer's dementia

Dementias are neurodegenerative conditions that affect millions of people worldwide. Among these, Alzheimer's disease is the most common form of dementia, characterized by extracellular amyloid plaques and neurofibrillary tangles of intraneuronal p-tau. This is currently an extremely important issue due to the global lack of disease-modifying treatments. For this reason, in recent years, the international medical community has been making substantial efforts to discover therapies that modify the disease, improve symp-toms, and treat the decompensations that occur in dementia. Innovative therapies, mono-clonal antibodies, vaccines targeting amyloid plaques, and even existing therapies that have been repurposed are currently being tested to see their effects in treating dementia. A diverse treatment profile, highlighted by a significant divergence between biological effi-cacy and clinical tolerability, is shown by analysis of data gathered in stages I and II. The findings demonstrate the intricacy of the therapeutic window in the treatment of Alzhei-mer's disease and the necessity of striking a careful balance between patient safety and pharmacological potency. The amyloid hypothesis is validated by the removal of patho-genic protein deposits, although titration techniques and patient selection criteria need to be improved due to the heterogeneity of adverse effects. The shift to crucial phase III re-search, which aims to determine the therapeutic significance of biomonitored plaque re-duction on functional cognitive decline, is supported by these data.